Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia

NCT03258866 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT03258866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03258866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia
Lead sponsor
Shandong University
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2010
Completion date
December 31, 2016
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia, purpura, thrombocytopenic, idiopathic